![](/img/cover-not-exists.png)
Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective
Stellato, Daniel, Gerbasi, Margaret E., Ndife, Briana, Ghate, Sameer R., Moynahan, Aaron, Mishra, Dinesh, Gunda, Praveen, Koruth, Roy, Delea, Thomas E.Volume:
25
Language:
english
Journal:
Journal of Managed Care & Specialty Pharmacy
DOI:
10.18553/jmcp.2019.25.11.1227
Date:
November, 2019
File:
PDF, 254 KB
english, 2019